Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors ...

The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

In resectable lung cancer, neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival, with no lung cancer deaths reported at 5 years in patients with a pathological complete response.

In this randomized trial, the inhaled recombinant human GM-CSF molgramostim improved pulmonary gas transfer in patients with autoimmune pulmonary alveolar proteinosis.

Methods In this phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with aPAP to receive molgramostim at a dose of 300 μg or placebo once daily for 48 weeks. The ...

In this trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate- ...

In high-risk cutaneous squamous-cell carcinoma, adjuvant cemiplimab prolonged disease-free survival and reduced recurrence risk as compared with placebo. No new safety concerns with cemiplimab ...

A 32-year-old woman presented with fatigue, myalgias, and palpitations. The cardiac rhythm was irregularly irregular, and an electrocardiogram showed findings suggestive of grouped beating. A diagn ...

High-risk cutaneous squamous-cell carcinoma has a substantial risk of recurrence after surgery and radiotherapy. New research findings on adjuvant cemiplimab therapy are summarized in a short video.

Inhaled molgramostim showed promise for treating patients with autoimmune pulmonary alveolar proteinosis in an early trial. New research findings from a phase 3 trial are summarized in a short video.

Neoadjuvant nivolumab plus chemotherapy has previously been shown to improve pathological response in resectable non–small-cell lung cancer. New research findings on overall survival at 5 years ...